T cell receptor gamma variable 5P (pseudogene)Genealiases: TCRGV5P · V1S5P
Q-omics provides the consensus-scored TRGV5P profile across patient tissues and cancer cell-line models. TRGV5P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TRGV5P is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, TRGV5P RNA expression shows 12,781 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight SKCM, KIRC, and DLBC as cancer lineages where TRGV5P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRGV5P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRGV5P survival associations across molecular data types. TRGV5P RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRGV5P RNA expression–survival associations across cancer types. High TRGV5P expression shows unfavorable associations in UVM, ACC and LGG, but favorable associations in SKCM, LUAD and BLCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TRGV5P RNA expression.
This table summarizes TRGV5P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRGV5P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRGV5P shows lower tumor expression in LUSC, COAD and KICH and higher tumor expression in KIRC, STAD and HNSC. The KIRC box plot shows higher TRGV5P RNA expression in tumor versus normal tissue (log2 FC = +0.264, t-test p < 0.001).
This table shows molecular features associated with TRGV5P in patient tissues and cancer cell lines. In patient samples, TRGV5P shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
